Evidence map›Paper›PMID 32257866›Full record

ReviewTranslational andrology and urology2020

The good, bad, and the ugly of regenerative therapies for erectile dysfunction.

Jeffrey D Campbell, Uros Milenkovic, Mustafa Faruk Usta, Maarten Albersen, Trinity J Bivalacqua

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Canadian Urological Association guideline: Erectile dysfunction.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Evidence of restorative therapies in the treatment of Peyronie disease: A narrative review.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Jeffrey D CampbellDepartment of Surgery, Division of Urology, Western University, London, ON, Canada.
Uros MilenkovicLaboratory for Experimental Urology, Department of Development and Regeneration, University of Leuven, Leuven, Belgium.
Mustafa Faruk UstaDepartment of Urology, Section of Andrology, Akdeniz University School of Medicine, Antalya, Turkey.
Maarten AlbersenLaboratory for Experimental Urology, Department of Development and Regeneration, University of Leuven, Leuven, Belgium.
Trinity J BivalacquaThe James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
KU Leuven · BEAkdeniz University · TRJohns Hopkins University · USWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erectile dysfunction (ED) is a common condition which reduces quality of life of both patients and their partners, and is a significant health care expense every year. Although phosphodiesterase type-5 inhibitors are the current first-line treatment for men with ED, they are limited by their on-demand dosing, intolerance, and variable efficacy in complex patient populations such as men with multiple medical comorbidities or ED after pelvic surgery. Regenerative medicine has been introduced and investigated in andrology as an encouraging strategy to restore diseased erectile tissue structure and function. Novel regenerative therapies for ED are controversial but are perceived to offer a durable and safe tissue restorative approach to act as a long-term solution to this cumbersome disease process. Here, we review platelet-rich plasma, amniotic fluid membranes, low-intensity extracorporeal shockwave therapy, and stem cell therapy as regenerative strategies to treat ED. Most of these approaches have preclinical and occasionally clinical data to support their ongoing investigation; however, none of these treatments are currently supported for use in ED patients outside of clinical trials.

Indexed as

amniotic fluidchorion graftsErectile dysfunction (ED)low-intensity extracorporeal shockwave treatmentplatelet-rich plasmastem cell therapy

Identifiers

PMID32257866
PMCPMC7108995
OpenAlexW2982558809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.